Evidence map›Paper›PMID 29926508›Full record

ArticleHealth economics2018

The effect of HIV prevention products on incentives to supply condomless commercial sex among female sex workers in South Africa.

Matthew Quaife, Peter Vickerman, Shanthi Manian, Robyn Eakle, Maria A Cabrera-Escobar, Sinead Delany-Moretlwe, Fern Terris-Prestholt

Open access · hybridAbstract read
In one paragraph

Article in Health economics, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed, 1 pooled it
7.7field-weighted citation impact, top 3% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed, 1 synthesis or guideline pooled it, 24 citations in OpenAlex.

  1. Pooled it
  2. Trial
  3. Trial
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Article
  11. Article
  12. Article
  13. Article
  14. Article
  15. Article
  16. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors at 4 institutions in 3 countries.

Matthew QuaifeDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.ORCID 0000-0001-9291-1511
Peter VickermanSchool of Social and Community Medicine, University of Bristol, Bristol, UK.
Shanthi ManianWashington State University, Pullman, Washington, USA.
Robyn EakleDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
Maria A Cabrera-EscobarWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Sinead Delany-MoretlweWits RHI, University of the Witwatersrand, Johannesburg, South Africa.
Fern Terris-PrestholtDepartment of Global Health and Development, London School of Hygiene and Tropical Medicine, London, UK.
University of the Witwatersrand · ZALondon School of Hygiene & Tropical Medicine · GBUniversity of Bristol · GBWashington State University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Evidence suggests that economic factors play an important role in commercial sex work, in particular that condomless sex commands a price premium relative to condom-protected sex. This paper explores whether the use of a new HIV prevention product, with 100% efficacy but modeled after pre-exposure prophylaxis (PrEP), could change the price and quantity of condomless commercial sex supplied. We collected stated preference data from 122 HIV-negative female sex workers in urban South Africa, using a repeated choice experiment to simulate the impact of using PrEP on choices. Results suggest that the price premium for condomless sex would decrease by 73% with PrEP use and the quantity of condomless sex is predicted to increase by a factor of 2.27. Act price does not significantly affect choices without protection but strongly influences choices under full HIV protection. The utility offered by condoms reduces by around 15% under PrEP use. Because new HIV prevention products do not protect against other STIs or pregnancy, the unintended consequences of introducing HIV prevention products should be closely monitored, whereas users should not face stigma or blame for reacting rationally to exogenous changes to market conditions.

Indexed as

MotivationAdultCondomsFemaleHIV InfectionsHumansModels, EconomicPre-Exposure ProphylaxisSafe SexSex WorkersSouth Africacondom differentialeconomics of sex workHIV preventionrisk compensationSouth Africa

Identifiers

PMID29926508
PMCPMC6175015
OpenAlexW2808778399

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.